Multiple endocrinopathies associated with lithium therapy

Endocrine Practice

Volumn 13, Issue 7, 2007, Pages 758-763

  Dalan, Rinkoo ^a   Leow, Melvin Khee Shing ^a   Jong, Michelle ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; LITHIUM; THYROTROPIN; THYROXINE;

ADENOMA; AGED; ARTICLE; BLOOD; CASE REPORT; CHEMICALLY INDUCED DISORDER; ENDOCRINE DISEASE; FEMALE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTHYROIDISM; NEPHROGENIC DIABETES INSIPIDUS; PARATHYROID TUMOR; PARATHYROIDECTOMY; URINE;

ADENOMA; AGED; CALCIUM; DIABETES INSIPIDUS, NEPHROGENIC; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTHYROIDISM; LITHIUM; PARATHYROID NEOPLASMS; PARATHYROIDECTOMY; THYROTROPIN; THYROXINE;

EID: 38949172906     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.7.758     Document Type: Article

References (38)

1. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;36:349-352.
2. Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy - a cross sectional study and the effect of lithium withdrawal. J Intern Med. 1996;240:357-365.
3. Heath H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism: incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302:189-193.
4. Nordenström J, Elvius M, Bågedahl-Strindlund M, Zhao B, Törring O. Biochemical hyperparathyroidism and bone mineral status in patients treated long-term with lithium. Metabolism. 1994;43:1563-1567.
5. Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol (Oxf). 1994;40:759-764.
6. Bendz H, Aurell M. Drug-induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999; 21:449-456.
7. Bendz H, Sjödin I, Aurell M. Renal function on and off lithium in patients treated with lithium for 15 years or more: a controlled, prospective lithium withdrawal study. Nephrol Dial Transplant.. 1996;11:457-460.
8. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10:329-345.
9. McIntosh WB, Horn EH, Mathieson LM, Sumner D. The prevalence, mechanism and clinical significance of lithium-induced hypercalcaemia. Med Lab Sci. 1987;44: 115-118.
10. Mallette LE, Eichhorn E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med. 1986;146: 770-776.
11. Kallner G, Petterson U. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1-30 years. Acta Psychiatr Scand. 1995;91:48-51.
12. Racke F, McHenry CR, Wentworth D. Lithium-induced alterations in parathyroid cell function: insight into the pathogenesis of lithium-associated hyperparathyroidism. Am J Surg. 1994;168:462-465.
13. Birnbaum J, Klandorf H, Giuliano A, Van Herle A. Lithium stimulates the release of human parathyroid hormone in vitro. J Clin Endocrinol Metab. 1988;66:1187-1191.
14. Haden ST, Stoll AL, McCormick S, Scott J, Fuleihan Gel-H. Alterations in parathyroid dynamics in lithium-treated subjects. J Clin Endocrinol Metab. 1997;82:2844-2848.
15. Dwight T, Kytölä S, Teh BT, et al. Genetic analysis of lithium-associated parathyroid tumors. Eur J Endocrinol. 2002;146:619-627.
16. Mak TW, Shek CC, Chow CC, Wing YK, Lee S. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab. 1998;83:3857-3859.
17. Wolf ME, Moffat M, Mosnaim J, Dempsey S. Lithium therapy, hypercalcemia and hyperparathyroidism. Am J Ther. 1997;4(9-10):323-325.
18. Carney S, Jackson P. Acute lithium administration impairs the action of parathyroid hormone on rat renal calcium, magnesium and phosphate transport. Clin Exp Pharmacol Physiol. 1998;25:795-799.
19. Salata R, Klein I. Effects of lithium on the endocrine system: a review. J Lab Clin Med. 1987;110:130-136.
20. Shoback D, Marcus R, Bikle D. Metabolic bone disease. In: Greenspan FS, Gardner DG, eds. Basic and Clinical Endocrinology. 7th ed. San Francisco, CA: The McGraw-Hill Companies Inc, 2004: 295-361.
21. Awad SS, Miskulin J, Thompson N. Parathyroid adenoma versus four-gland hyperplasia as the cause of primary hyperparathyroidism in patients with prolonged lithium therapy. World J Surg. 2003;27:486-488.
22. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J Psychopharmacol. 2006;20:347-355.
23. Berens SC, Bernstein RS, Robbins J, Wolff J. Antithyroid effects of lithium. J Clin Invest. 1970;49:1357-1367.
24. Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta. 1978;542:163-169.
25. Bocchetta A, Bernardi F, Pedditzi M, et al. Thyroid abnormalities during lithium treatment. Acta Psychiatr Scand. 1991;83:193-198.
26. Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf). 2001;55:501-508.
27. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord. 2005;87(2-3):313-317.
28. Mizukami Y, Michigishi T, Nonomura A, Nakamura S, Noguchi M, Takazakura E. Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol. 1995;48:582-584.
29. Mukhopadhyay D, Gokulkrishnan L, Mohanaruban K. Lithium-induced nephrogenic diabetes insipidus in older people. Age Ageing. 2001;30:347-350.
30. Bendz H, Aurell M, Balldin J, Mathé AA, Sjödin I. Kidney damage in long-term lithium patients: a cross-sectional study of patients with 15 years or more on lithium. Nephrol Dial Transplant.. 1994;9:1250-1254.
31. Christensen BM, Marples D, Kim YH, Wang W, Frøkiaer J, Nielsen S. Changes in cellular composition of kidney collecting duct cells in rats with lithium-induced NDI. Am J Physiol Cell Physiol. 2004;286:C952-C964.
32. Martin A. Clinical management of lithium-induced polyuria. Hosp Community Psychiatry. 1993;44:427-428.
33. Finch CK, Kelley KW, Williams RB. Treatment of lithium-induced diabetes insipidus with amiloride. Pharmacotherapy. 2003;23:546-550.
34. Brooks SC, Lessin BE. Treatment of resistant lithium-induced nephrogenic diabetes insipidus and schizoaffective psychosis with carbamazepine. Am J Psychiatry. 1983; 140:1077-1078.
35. Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr. 1986;108:305-311.
36. Grønbeck L, Marples D, Nielsen S, Christensen S. Mechanism of antidiuresis caused by bendroflumethiazide in conscious rats with diabetes insipidus. Br J Pharmacol. 1998;123:737-745.
37. Ashrafian H, Bogle RG. Sensitizing the insensitive. Clin Nephrol. 2004;61:440-443.
38. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.